---
title: "Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688488.SH.md"
symbol: "688488.SH"
name: "Jiangsu Aidea Pharmaceutical Group Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T11:53:11.117Z"
locales:
  - [en](https://longbridge.com/en/quote/688488.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688488.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688488.SH.md)
---

# Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH)

## Company Overview

Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.aidea.com.cn](https://www.aidea.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 33.77% |  |
| Net Profit YoY | 75.44% |  |
| P/B Ratio | 6.90 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6706983107.75 |  |
| Revenue | 697988526.65 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.79% | D |
| Profit Margin | -3.93% | D |
| Gross Margin | 67.52% | A |
| Revenue YoY | 33.77% | A |
| Net Profit YoY | 75.44% | A |
| Total Assets YoY | 8.64% | B |
| Net Assets YoY | -0.26% | D |
| Cash Flow Margin | 77.17% | C |
| OCF YoY | 33.77% | A |
| Turnover | 0.35 | D |
| Gearing Ratio | 47.08% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Aidea Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "33.77%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "75.44%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.90",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6706983107.75",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "697988526.65",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.79%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-3.93%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "67.52%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "33.77%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "75.44%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.64%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.26%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "77.17%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "33.77%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "47.08%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -244.29 | 79/81 | - | - | - |
| PB | 6.90 | 61/81 | 7.42 | 6.63 | 6.01 |
| PS (TTM) | 9.61 | 46/81 | 11.65 | 10.53 | 9.61 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-09-26T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.46 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688488.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688488.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688488.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**